B
Banu Aygun
Researcher at Children's Medical Center of Dallas
Publications - 100
Citations - 3229
Banu Aygun is an academic researcher from Children's Medical Center of Dallas. The author has contributed to research in topics: Sickle cell anemia & Anemia. The author has an hindex of 29, co-authored 90 publications receiving 2661 citations. Previous affiliations of Banu Aygun include Hofstra University & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial
Russell E. Ware,Barry R. Davis,William H. Schultz,R. Clark Brown,Banu Aygun,Sharada A. Sarnaik,Isaac Odame,Beng Fuh,Alex George,William Owen,Lori Luchtman-Jones,Zora R. Rogers,Lee Hilliard,Cynthia Gauger,Connie M. Piccone,Margaret T. Lee,Janet L. Kwiatkowski,Sherron M. Jackson,Scott T. Miller,Carla W. Roberts,Matthew M. Heeney,Theodosia A. Kalfa,Stephen C. Nelson,Hamayun Imran,Kerri Nottage,Ofelia A. Alvarez,Melissa Rhodes,Alexis A. Thompson,Jennifer A. Rothman,Kathleen J. Helton,Donna R. Roberts,Jamie L. Coleman,Melanie J. Bonner,Abdullah Kutlar,Niren Patel,John C. Wood,Linda B. Piller,Peng Wei,Judy Luden,Nicole A. Mortier,Susan E. Stuber,Naomi L.C. Luban,Alan R. Cohen,Sara L. Pressel,Robert J. Adams +44 more
TL;DR: High-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocity and help to prevent primary stroke.
Journal ArticleDOI
Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
Banu Aygun,Savitri Padmanabhan,Savitri Padmanabhan,Carole Paley,Carole Paley,Visalam Chandrasekaran,Visalam Chandrasekaran +6 more
TL;DR: The clinical significance of alloimmunization to RBC antigens in sickle cell patients was analyzed by a retrospective review of the records of pediatric and adult sicklecell patients who received transfusions and who were followed over a 10‐year period.
Journal ArticleDOI
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa
Léon Tshilolo,George Tomlinson,Thomas N. Williams,Brigida Santos,Peter Olupot-Olupot,Adam Lane,Banu Aygun,Susan E. Stuber,Teresa Latham,Patrick T. McGann,Russell E. Ware +10 more
TL;DR: Hydxyurea treatment was feasible and safe in children with sickle cell anemia living in sub‐Saharan Africa and reduced the incidence of vaso‐occlusive events, infections, malaria, transfusions, and death, which supports the need for wider access to treatment.
Journal ArticleDOI
A global perspective on sickle cell disease.
Banu Aygun,Isaac Odame +1 more
TL;DR: Long‐term North–South and South–South partnerships between SCD professionals, funding agencies, governments, and industry are needed to help reduce the high disease burden in developing countries, through widespread SCD education, relevant research and implementation of evidence‐based cost‐effective interventions.
Journal ArticleDOI
Advances in the use of hydroxyurea
Russell E. Ware,Banu Aygun +1 more
TL;DR: Hydroxyurea is currently prescribed only sparingly for patients with sickle cell disease and therefore has only limited effectiveness for this disorder; barriers to its use need to be identified and overcome.